; (4) each laboratory that has the capability, capacity, and testing-related supplies to process COVID–19 diagnostic tests, including test type and location by State, territory, or Indian Tribe; (5) for each COVID–19 diagnostic test listed under paragraph (1), the time required to receive test results, including any time for processing and shipping, measured in the smallest unit of measurement reasonable for the particular test, whether minutes, hours, or days; (6) for each COVID–19 diagnostic test listed under paragraph (1), the approximate time per employee required to run the test; (7) for each COVID–19 diagnostic test listed under paragraph (1), each test that the Secretary has authorized, cleared, or approved under the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 301 et seq.), or is marketed in accordance with applicable guidance issued by the Secretary; (8) a list of each laboratory, hospital, and other health care facility that has reported a shortage of testing-related supplies, and which such supplies reported to be in shortage; (9) for each COVID–19 test manufacturer— (A) the number and type of COVID–19 diagnostic tests for which such manufacturer has— (i) current inventory and projected production capacity for the next 180 days for at least the 180-day period following the date on which such information is submitted; and (ii) received orders, including orders they do not have capacity to deliver; and (B) a description of materials that are in shortage that are hindering production of COVID–19 diagnostic tests by amount and type of test; and (10) for each laboratory, hospital, and other health care facility that receives COVID–19 diagnostic tests, the number of samples collected per day and the number of results transmitted to patients (including results transmitted to health care providers for patients) per day.